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Management of Patients with 
Refractory Coeliac Disease
Paul J. Ciclitira and Alastair Forbes
Abstract
Coeliac disease (CD) is an immune-mediated disorder affecting the small 
intestine. The condition represents an intolerance to gluten. Removal of dietary 
gluten permits recovery, with a full recovery for the majority of affected subjects. 
A percentage of affected subjects who do not improve with a gluten-free diet are 
considered to have refractory coeliac disease (RCD). Refractory coeliac disease is 
subdivided into type 1, characterised by a polyclonal expansion of intraepithelial 
lymphocytes (IELs) that have a normal phenotype, and type 2 (RCD2) which 
exhibits IELs with a monoclonal phenotype. Subjects with RCD carry a high risk 
of complications, including ulcerative jejunitis and lymphoma affecting the small 
intestine, the latter termed enteropathy-associated T-cell lymphoma (EATL).
Keywords: coeliac disease, refractory coeliac disease, presentation, diagnosis and 
treatment
1. Introduction
Coeliac disease (CD) represents an enteropathy affecting the small intestine 
that is exacerbated by gluten in wheat, rye and barley. The condition occurs in 
genetically susceptible individuals who carry either the HLA DQ2 or DQ8 geno-
type. [1] The prevalence of the condition, of which there is increasing awareness, is 
1–2% in the US and Northern Europe. [2, 3]. Treatment of the condition comprises 
a gluten-free approach that involves removal of wheat, rye and barley from the 
diet. However, between 5 and 30% of affected subjects do not fully respond to a 
gluten-free diet, [2–6] and are considered to have refractory coeliac disease (RCD).
The precise diagnosis of RCD presents challenges, but is important in the  
development of new therapeutic strategies. [7–9]
2. Pathogenesis of RCD
Gluten proteins from wheat, rye and barley are divided into different groups. 
Wheat gluten comprises gliadin and glutenin. There are α, β, γ and ω gliadin 
fractions, and glutenin is composed of low and high molecular weight glutenins 
(HMWG). All these components of wheat gluten have been shown to be toxic to 
subjects with CD. [9]
In CD there is increased permeability of the small intestine associated with an 
increase in zonulin, a protein found between enterocytes that has been reported 
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to be a modulator of tight junction permeability. [10, 11] It has been hypothesised 
that zonulin release induces increased absorption, into the lamina propria below 
the epithelium, of CD-toxic gluten fractions. The resultant gluten peptides in the 
lamina propria “stimulate aberrant adaptive and innate responses resulting in 
damage to the enterocytes, with infiltration of the mucosa by both intra-epithelial 
lymphocytes (IELs) and CD4 +ve lamina propria lymphocytes”. Most of the 
increased number of IELs are CD3 + ve/CD8 + ve cells that express the α/β T-cell 
receptor (TCR), and a minority are γ/𝛿 +ve (TCR)-expressing lymphocytes.
The adaptive response involves binding of the CD toxic peptides to HLA-DQ2 or 
HLA-DQ8. These reactive CD4 T-cells in the lamina propria recognise toxic gluten 
peptides and proteins. [12, 13] There is recognition of the gluten peptides bound 
to HLA-DQ2/DQ3, and to antigen presenting cells (APCs); this is enhanced by 
the enzyme tissue transglutaminase (tTg) that deamidates glutamine residues to 
glutamic acid [12]. Following activation of the T-cells, pro-inflammatory cytokines, 
including interferon-γ, are released. This in turn results in an inflammatory cas-
cade, particularly affecting the proximal small intestine, that causes the observed 
villous atrophy [13].
The innate immune response appears to be mediated by IELs, enterocytes 
and dendritic cells, and is centred on increased secretion of the cytokine inter-
leukin-15 (IL–15) [14]. It is possible that IL-15 production by enterocytes and 
dendritic cells is induced directly by gluten peptides. IL-15 stimulates the expres-
sion of MICA (a stress molecule) on enterocytes, and NKG2D (a natural killer 
receptor) on IELs. The IEL-induced NKG2D expression serves as an activating 
receptor with many ligands, including MICA [15]. In combination there may then 
be substantial cytotoxicity to enterocytes and thus the intestinal damage that is 
typical of CD.
It seems likely that RCD and uncomplicated CD have similar aetiopathogenic 
pathways. [14, 16] Most patients with RCD have increased levels of antigliadin 
and endomysial antibodies, although in RCD2 coeliac serology may become nega-
tive. Differentiation between RCD1 and RCD2 is based on evidence of either the 
polyclonal expansion of T-cells expression that occurs in RCD1, or the monoclonal 
expansion of T-cells in small intestinal biopsies or separated T-lymphocytes that 
can be demonstrated using double CD3/CD8 immuno-histochemistry in RCD2. An 
investigation of T-cell receptor clonal arrangements can be investigated by poly-
merase chain reaction on fresh tissue or by flow cytometry. [17–20]
The mechanisms behind the clonal expansion of T-cells in RCD2 are not well 
understood but there are several possibilities under active consideration. Genetic 
variation in the myosin IXB gene (MY09B) located on chromosome 19, has been 
proposed as a possible aetiopathological factor. [21] There is increased repairing of 
MICA and c-myc by the enterocytes [21–26]. An increase in IgM, Charcot-Leyden 
crystal proteins and apolipoprotein are observed and thought to be damaging in 
RCD2. [25] APO C3 apolipoprotein is also known to affect immunosurveillance 
cells, such as natural killer (NK) cells, and was singled out as potentially important 
in sustaining T-cell proliferation. [27]
IL-15 is overexpressed in untreated CD, and it is thought to play a pivotal role in 
the regulation of the IELs that characterise the disease and hence in in the patho-
genesis of RCD. IELs show increased expression of IL-15Rα, elevated proliferation 
cytokine production and a reduction in apoptosis. [19]. It has been suggested also 
that IL-15 may induce the emergence of a clonal expression [19]. This multistep 
transformation may generate the pre-lymphomatous state and then progress to 
overt T-cell lymphoma [27]. Inhibition of IL-15 may have therapeutic value in RCD2 
(see below) adding further weight to its suspected pathogenic importance.
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3. Clinical features of RCD
3.1 Type 1 refractory coeliac disease
Patients with RCD1 may present with any combination of steatorrhoea, altered 
bowel habit (with both constipation and diarrhoea), abdominal pain, nausea, 
fatigue and weight loss [28]. RCD1 is also associated with thromboembolic infec-
tious complications and autoimmune diseases. The radiological features on CT or 
MR scanning are similar to those of untreated CD, with increased ileal folds and 
decreased jejunal folds [29].
Patients with RCD1 exhibit Marsh type II or III appearances. [30] Both of these 
pathological gradings include villous atrophy. There is a moderate lymphoplasma-
cytic infiltrate in the lamina propria. [26] Collagen deposition (collagenous sprue) 
has been reported in 40% of patients with RCD1 [31]; this can be confirmed with a 
trichrome stain. Mucosal thinning with villous atrophy and crypt hyperplasia was 
reported in 30% of these patients.
The RCD1 IEL phenotype is equivalent to uncomplicated CD, with the majority 
of cells expressing CD3, CD7, CD8, CD103, and TCRβ. TCR gene rearrangement 
studies confirm that RCD1 cells constitute a polyclonal population. [28–32]
3.2 Type 2 refractory coeliac disease
RCD2 patients present with similar symptoms to those with RCD1, including 
malabsorption, weight loss, abdominal pain and diarrhoea. Most patients are aged 
50–60. [28] The CT/MR appearances are similar to those in RCD1, but frequently 
also include lymphadenopathy, intussusception and hyposplenism. [29]
The standard histology of RCD2 mirrors RCD1, with the majority of patients 
demonstrating a degree of villous atrophy [30]. The cytological appearances of the 
IELs are normal. Cellier et al. [14] proposed that RCD2 (their refractory sprue) was 
associated with an abnormal subset of IELs that, on frozen section, were posi-
tive for CD103, CD7, and cytoplasmic CD3, but not for surface CD3, CD4, CD8, 
or TCRβ. This difference from RCD1 has contributed to the concept that RCD2 
represents an early stage in the development of lymphoma. Aberrant IELs may also 
be found in gastric and colonic mucosa, and in the blood of RCD2 patients, imply-
ing that this is a diffuse gastrointestinal disease. The IELs in RCD2 patients rarely 
exhibit a normal CD3 + ve, CD8 + ve phenotype, and the majority have a CD3 + ve 
CD8 -ve pattern. However Goerres et al. [22] reported only a low frequency of 
loss of CD8 expression, and it is advocated that flow cytometry should be used to 
diagnose the condition.
Although a polyclonal IEL population has been reported in a very small propor-
tion of RCD2 cases, it is usual to find monoclonality with a restricted rearrangement 
of the TCRβ gene when clonality studies are performed in RCD2.
4. Complications of RCD
4.1 Ulcerative Jejunitis
Most cases of ulcerative jejunitis (UJ) are preceded by problematic CD, such 
that UJ can be said to evolve from RCD. The mean age at onset of UJ is 50 years. 
The defining features are ulcerative lesions that are usually multifocal and which 
can involve the ileum as well as the jejunum. Presenting features include diarrhoea, 
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steatorrhoea, abdominal pain and weight loss. There may be low grade fever, club-
bing and nutritional deficiencies.
Mills et al. reported that the ulceration can extend through the full thickness of 
the mucosa, with secondary vascular changes [31] as well as submucosal oedema. 
There may also be fibrosis, leading to stricture formation. Complications can thus 
include haemorrhage, perforation and obstruction.
In some patients there is gastric metaplasia, and it is postulated that this con-
tributes to ulcer formation. Most IELs in UJ have a phenotype identical to that of 
RCD2. The ulcers tend to show a mixed CD4 + ve/CD8 + ve and CD4-ve/CD8-ve 
phenotype. T-cell rearrangement studies identify clonality in the ulcers, the adja-
cent mucosa, or in both.
4.2 Enteropathy-type T-cell lymphoma
There is an increased risk of B- and T-cell lymphoma in coeliac disease. 
Enteropathy-associated T-cell lymphoma (EATL) is particularly linked to CD [29]. 
EATL usually presents with abdominal pain or overt intestinal perforation in adults 
with a background of RCD2 or UJ [33]. The strong association of EATL with HLA-
DQB1 strengthens the inferred causal linkage between CD and EATL [33–36].
There are two main histological types of EATL. Type 1 is characterised by an 
infiltrate of medium sized cells containing round or angular nuclei with promi-
nent nucleoli and a moderate amount of eosinophilic cytoplasm [33]. There may 
be marked pleomorphism with appearances like those of large-cell lymphoma or 
Hodgkin’s lymphoma. The second, rarer type of EATL exhibits a monomorphic 
population of small, densely staining cells with hyperchromatic nuclei and minimal 
cytoplasm.
The malignant cells of both forms of EATL demonstrate monoclonality, with the 
same TCRγ gene rearrangement as seen in IELs in intestinal mucosa affected by the 
CD but which is uninvolved in the malignancy.
4.3 Other types of lymphoma
In addition to EATL, other types of non-Hodgkin’s lymphoma are over-represented 
in patients with CD. Subtypes observed include B-cell neoplasms, follicular lym-
phoma, extranodal marginal zone lymphoma, and T-cell neoplasms.
4.4 Carcinoma of the GI tract
CD has an association with small bowel adenocarcinoma, which usually presents 
after the age of 45, with abdominal pain, weight loss, and/or anaemia. There is also 
an increased risk of squamous cell carcinoma of the upper digestive tract, including 
the oesophagus and oropharynx. There are minimally increased risks of primary 
liver cancer and of colorectal cancer.
5. Diagnostic approach to RCD
There are many reasons for patients with CD to fail to respond to a gluten-free 
diet, of which an underlying diagnosis of RCD is only one. [34] Poor dietary com-
pliance and potential confusion of CD with other conditions should be excluded.
It has been suggested that a minimum of three properly orientated crypt to 
villous units are necessary for reliable interpretation of villous atrophy [34]. 
Helicobacter pylori, giardia, tuberculosis, tropical sprue, Whipple’s disease, viral 
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enteritis, AIDS, autoimmune enteritis, food protein intolerance, Crohn’s disease, 
common variable immunodeficiency, collagenous sprue and eosinophilic gastroen-
teritis may all mimic CD [34]. Their exclusion from the differential diagnosis is not 
always straightforward when histological criteria are ambivalent or when multiple 
conditions co-exist (eg CD and infection).
The diagnosis of RCD runs in parallel with that of an initial comprehensive diagno-
sis of CD, which will therefore be briefly reprised. Coeliac serology should be obtained, 
with IgA and IgG antibodies to tissue transglutaminase and endomysium. Gliadin 
antibodies are unhelpful as IgG gliadin antibodies are raised in 5% of normal sub-
jects, and in many of the conditions documented above, particularly Crohn’s disease. 
HLA DQ2/DQ8 studies should be undertaken. A set of intestinal biopsies should be 
obtained for histological assessment. These endoscopic biopsies should be repeated 
after 4–6 months to confirm the diagnosis, and when RCD is suspected. [15]
In addition to evidence of villous atrophy, the biopsies will be examined for 
increased intraepithelial lymphocytes. The suggested normal upper limit for the 
small intestinal mucosa is 25 IELs per 100 enterocytes, with 25–29 considered 
borderline, and ≥ 30 IELs regarded as pathological lymphocytosis. In the normal 
small intestine there is a gradual reduction in the density of IELs between the bases 
and tips of the villi [37, 38]; a more even distribution of IELs along the lengths of 
the villi is strongly suggestive of underlying active CD [38, 39]. There is however a 
wide range of other conditions which cause intra-epithelial lymphocytosis, includ-
ing H. pylori infection, enteric infarction, and autoimmune disease, and this may 
also occur with non-steroidal anti-inflammatory or other drugs.
According to the ESPGHAN diagnostic algorithm, the combination of a typical 
history, HLA-DQ2/8 positivity and coeliac serology at >10 x normal levels con-
stitutes a diagnosis of coeliac disease in children [35]. Consequent to the COVID 
pandemic, the same diagnostic algorithm is now proposed for adults with symptoms 
of CD so long as they are ≤55 years of age, have no red flag symptoms, have a normal 
total IgA level, have an IgA tTG ≥ 10 times upper limit of normal, and a second posi-
tive antibody test such as anti-endomysial antibodies. However, most gastroenterol-
ogists feel this approach should only be temporary, as there is frequently discrepancy 
between the results of serology and small intestinal morphology [36, 40].
RCD will be considered in the patient who remains symptomatic or with persis-
tently abnormal laboratory markers after apparent compliance with a gluten-free 
diet. Clinico-pathological correlation should first be undertaken to ensure that the 
initial diagnosis of CD was fully supported, including HLA DQ2/8 status, anti-
endomysial and tissue transglutaminase antibodies, together with the presence of 
small bowel lesions, with particular attention to any history of a previous response to 
a gluten-free diet. RCD is however a histological diagnosis. Histological assessment 
will be particularly important where the initial diagnosis was made without a biopsy.
Appraisal of the gluten-free diet is crucial when contemplating RCD, as gluten 
contamination is the commonest cause of failure to respond to a gluten free diet. 
Contamination can be asymptomatic with minimal quantities, and can occur 
in patients who have received poor advice or are unaware of the broad range of 
products that can contain gluten [28].
In the absence of an aberrant IEL immunophenotype, the main differential diag-
nosis of CD-like histological lesions is limited to uncomplicated but inadequately 
treated CD, and RCD1. If there was no prior histology giving a diagnosis of CD, 
then a history of a previous response to a gluten-free diet is naturally highly sup-
portive [28–36]. Both CD and RCD1 exhibit a polyclonal increase in IELs, mostly a 
CD3 + ve/CD8 + ve IEL population. Persistence or recurrence of small bowel lesions 
of this type, despite strict adherence to a gluten-free diet for at least one year, fulfils 
most observers’ criteria for a diagnosis of RCD1.
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The demonstration of a predominant CD3 + ve/CD8-ve aberrant IEL pheno-
type leads to the consideration of RCD2 and its complications, including EATL. 
Polymerase chain reaction assessment of IELs and flow cytometry are now widely 
used to complement immunohistochemistry in the diagnosis of RCD2. These 
studies illustrate the importance of immune regulation in the likely pathogenesis of 
RCD and of RCD2 in particular.
Focal neoplasia (EATL and other forms) may be difficult to identify within the 
diffusely abnormal small intestine found in RCD2. Video capsule endoscopy, and 
PET-CT tomography scanning have been shown to be more effective in pinpointing 
EATL than CT alone. Video capsule endoscopy and subsequent enteroscopy are par-
ticularly useful in detecting the more subtle lesions that may be the only macroscopic 
evidence of an underlying lymphoma. Elwenspoel et al propose to undertake an 
assessment of the accuracy of all potential diagnostic routes for coeliac disease and 
its complications involving a systematic review, the results of which are awaited [41].
6. Treatment of RCD
6.1 RCD1
All RCD patients should be reviewed by an expert dietitian in order to help them 
maximise their ability to adhere to a strict gluten-free diet.
In RCD1 the addition of systemic steroids has proven useful in some patients. 
The anti-TNFα biologic infliximab has also been proposed for the treatment of 
resistant coeliac disease [42]. Subsequent proposals have suggested a regimen of 
prednisolone and azathioprine that led to histological and clinical improvement in 
the majority of RCD1 patients following treatment for one year [22]. Dosages need 
some personalisation, but a tapering schedule of prednisolone (from 40 mg/day to 
less than 10 mg) with azathioprine at 2 mg/kg seem appropriate for most patients.
Use of an elemental diet not only provided clinical and histological improve-
ment, but also reduced epithelial expression of the cytokine IL-15.
The specific defect in permeability associated with zonulin excess appears to be 
improved on treatment with larazotide acetate. [11]
6.2 RCD2
Prednisolone/azathioprine has been found to be helpful in some patients with 
RCD2 [8, 22].
Chemotherapy agents, such as the anti T-cell nucleoside analogues including 
pentostatin and cladribine have also been used with some success. [43]
Recently, IAMG 714, a monoclonal antibody to IL-15, has been studied in a 
randomised, double-blind, placebo-controlled, parallel-group trial in patients with 
type 2 refractory coeliac disease [44, 45].
Stem cell transplantation has been proposed as a therapeutic option, but this 
invasive approach is not generally accepted.
Overt lymphoma will be treated on standard oncological criteria and will 
normally fall outside the responsibility of the gastroenterologist.
7. Conclusions
In conclusion, the diagnosis of RCD is not straightforward. This interpretation 
of the clinical picture may have been incorrect, and the original diagnosis should 
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always be reviewed, incorporating a re-assessment of the histology of small intesti-
nal biopsies. Assessment of the gluten-free diet and correlation with the results of 
serology should be undertaken. PCR evaluation of biopsies or separated lympho-
cytes can be used to differentiate between RCD1 and RCD2, the former resembling 
severe but uncomplicated CD, while the latter typically has monoclonality and 
potentially premalignant features.
Treatment options have included steroids, azathioprine, infliximab, cladribine, 
stem cell transplantation and humanised monoclonal antibody to IL-15, (IAMG 
714). There is to date no established standard intervention.
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Acronyms and non-standard abbreviations
APC  Anti-Presenting Cells
APO  Apolipoprotein
CD  Coeliac Disease
CT  Computed Tomography
EATL  Enteropathy-associated T-cell lymphoma
IELs  Intraepithelial lymphocytes
(Ig)A and (Ig)G  Immunoglobulins
IL  Interleukin
iNK  Invariant natural killer cells
MR  Magnetic resonance
NHL  Non-Hodgkin’s lymphoma
NK  Natural killer
RCD  Refractory coeliac disease
TCR  T-cell receptor
tTG  Tissue transglutaminase
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